Cart
sales@molnova.com
hDHODH-IN-1
CAS No. 1173715-42-8
hDHODH-IN-1( —— )
Catalog No. M26247 CAS No. 1173715-42-8
hDHODH-IN-1 is an inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an anti-inflammatory effect.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 215 | Get Quote |
|
| 10MG | 345 | Get Quote |
|
| 25MG | 582 | Get Quote |
|
| 50MG | 830 | Get Quote |
|
| 100MG | 1125 | Get Quote |
|
| 500MG | 2241 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamehDHODH-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionhDHODH-IN-1 is an inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an anti-inflammatory effect.
-
DescriptionhDHODH-IN-1 is an inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an anti-inflammatory effect.(In Vitro):Dihydroorotate dehydrogenase (DHODH) is a class-2 dihydroorotate dehydrogenase in human.?Inhibitors have been developed to eliminate human DHODH (hDHODH) activity, which is associated with cancers,inflammatory diseases , and autoimmune and multiple sclerosis because DHODH is required to ensure proliferating-cell viability.
-
In VitroHuman dihydroorotate dehydrogenase (hDHODH) is a class-2 dihydroorotate dehydrogenase. Because DHODH is required to ensure proliferating-cell viability, inhibitors have been developed to eliminate human DHODH (hDHODH) activity, which is associated with cancers, multiple sclerosis, and autoimmune and inflammatory diseases.
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetDehydrogenase
-
RecptorPEGs
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1173715-42-8
-
Formula Weight278.311
-
Molecular FormulaC17H14N2O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (898.28 mM)
-
SMILESC\C(O)=C(/C#N)C(=O)Nc1ccc(cc1)-c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
molnova catalog
related products
-
AGI-14100
AGI-14100 is a novel and orally available mIDH1 inhibitor.AGI-14100 is used for the treatment of primary human myeloid leukemia.
-
Etamicastat hydrochl...
Etamicastat hydrochloride (BIA 5-453 hydrochloride) is a peripherally selective dopamine beta-hydroxylase inhibitor that reduces hypertension.
-
CHIKV-IN-2
CHIKV-IN-2 shows inhibitory activity against a cellular target Dihydroorotate Dehydrogenase (DHODH), which interacts with various viruses and regulate their replication via depleting intracellular pyrimidine pools.
